Protillion Biosciences
Curtis Layton is the CEO and Co-Founder of Protillion Biosciences, a position held since May 2019. Prior to this, Curtis Layton served as a Research Scientist and Postdoctoral Research Fellow at Stanford University School of Medicine from February 2011 to May 2019. Earlier academic experience includes a Graduate Research Associate role at Duke University Medical Center from September 2003 to December 2010, where Curtis earned a Ph.D. in Computational Biology (Biochemistry). Curtis Layton's educational background comprises postdoctoral fellowships in Genetics and Biochemistry from Stanford University School of Medicine, as well as a B.S. in Zoology from Brigham Young University.
This person is not in any offices
Protillion Biosciences
Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.